Skip to content

Crinetics Pharmaceuticals CRNX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$496.39M-51.2%-$465.32M-55.9%-$423.1M-52.2%-$369.83M-43.0%-$328.25M-39.4%
$4.13M+27.5%$3.89M+39.7%$3.68M+63.1%$3.44M+95.3%$3.24M+151%
$100.23M+31.2%$91.02M+31.2%$88.15M+41.8%$83.59M+51.8%$76.41M+65.1%
-$414.17M-55.8%-$377.92M-64.2%-$351.89M-72.4%-$304M-66.4%-$265.79M-47.1%
$5.34M+42.4%$5.76M+49.9%$6.33M+68.9%$6M-10.8%$3.75M-37.5%
$7.51M+101%$173.91M+129%-$425.29M-202%-$590.1M-76.7%-$681.69M-174%
$426.05M-31.9%$40.61M-96.0%$570.81M+14.5%$625.05M-19.8%$625.52M-20.2%
-$419.52M-55.6%-$383.68M-63.9%-$358.23M-72.3%-$310M-63.7%-$269.54M-44.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Crinetics Pharmaceuticals's cash flow data come from?
Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.